Browsing by Author "Gulleroglu, Kaan"

Now showing 1 - 20 of 57

Abnormal circadian blood pressure regulation in children with nocturnal enuresis
(2016) Yuce, Ozge; Bayrakci, Umut Selda; Gulleroglu, Kaan; Baskin, Esra; 27056252
Introduction: To investigate autonomic nervous system function in enuretic children by performing ambulatory blood pressure monitor (ABPM) for 24h. Methods: Twenty-eight children ranging in age from 6 to 15 years with primary nocturnal enuresis and 27 age-matched healthy controls were enrolled and they get 24h ABPM. Hypertension was defined as standard deviation score (SDS)>1.64 (i.e., >95th percentile) adjusted for gender and height. Urinalysis, urine electrolyte levels, urinary culture, and urinary system ultrasound were carried out in all children. They have also requested to have a diary about daily fluid intake and urine volume. Results: Although the mean 24-h and daytime diastolic blood pressure (BP) did not differ between the groups, systolic BP (SBP) was significantly higher in enuretic children (p<0.05). The mean night-time SBP, DBP values, SDS and BP loads were found to be significantly higher than those in the controls (p<0.01). A lack of nocturnal decrease was more prevalent in the enuretic children compared with the control subjects, the difference was statistically significant for DBP but not for SBP. Patients with elevated night-time BP load was found to have higher frequency of urinary incontinence per week as well as per night when compared with enuretic children with normal night-time BP load (r=0.72, r=0.69, p<0.01, respectively). Conclusion: Subtle abnormalities of circadian BP regulation in enuretic children indicated by a selective elevation of nocturnal SBP, DBP, and MAP, and attenuated nocturnal dipping may reflect sympathetic hyper activation and its possible role in pathogenesis of enuresis.
Acute Rejection and Longterm Graft Survival in Pediatric Renaltransplant Patients
(2018) Baskin, Esra; Gulleroglu, Kaan; Sahin, Vildan; Kazanci, Ozlem; Moray, Gokhan; Haberal, Mehmet; 0000-0003-4361-8508; 0000-0003-1434-3824; 0000-0003-2498-7287; 0000-0002-3462-7632; B-5785-2018; AAJ-8833-2021; AAE-1041-2021; AAJ-8097-2021
Association Between Heat Shock Protein-72 Gene Polymorphism and Chronic Renal Failure in Children
(2014) Gulleroglu, Kaan; Baskin, Esra; Kantar, Asli; Sahin, Feride; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0001-7308-9673; F-3294-2013; B-5785-2018; AAC-7232-2020
Association Between Vitamin D Deficiency and Anemia in Pediatric Kidney Transplant Recipients
(2022) Avci, Begum; Baskin, Esra; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Karakaya, Emre; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-3462-7632; 0000-0002-4879-7974; 0000-0003-0774-4419; 35570598; AAJ-8833-2021; AAJ-8097-2021; AAD-5466-2021; AAD-1877-2021
Objectives: The association between vitamin D deficiency and anemia is known. Vitamin D deficiency and anemia are common in kidney transplant recipients. We examined the relationship between vitamin D levels and anemia in pediatric kidney transplant recipients. Materials and Methods: We reviewed retrospectively the data of 75 pediatric kidney transplant recipients (0-18 years of age). Patients were evaluated in 3 groups according to serum 25-hydroxyvitamin D levels (<20, 20-30, and >30 ng/mL) in the first year posttransplant: group 1 was the vitamin D deficiency group, group 2 was the vitamin D insufficiency group, and group 3 was normal vitamin D level group, respectively. Groups were compared in terms of anemia parameters, calcium, phosphorus, alkaline phosphatase, and parathyroid hormone levels, as well as infection, rejection, and graft loss status. All patients included in the study were grouped as those with anemia and without anemia, and the 2 groups were compared in terms of vitamin D levels, serum parathyroid hormone values, estimated glomerular filtration rate, and infection, rejection, and graft loss status. Results: There were 41 patients (54.7%) in group 1, 24 patients (32%) in group 2, and 10 patients (13%) in group 3. There were 65 patients (86.7%) with vitamin D deficiency/insufficiency. When groups were compared, the hematocrit level was found to be lower in groups 1 and 2 (P < .05) and ferritin level was found to be lower in group 1 (P < .05). Anemia was present in 20 patients (26.6%): 61% of patients with anemia had vitamin D deficiency and 33% had vitamin D insufficiency (P > .05). In total, 94% of patients with anemia had vitamin D deficiency/insufficiency. Conclusions: Vitamin D deficiency/insufficiency is common in pediatric kidney transplant recipients. Vitamin D levels should be measured, especially in all kidney transplant recipients with persistent anemia. Thus, risk factors associated anemia can be reduced by treating the deficiency/insufficiency.
Association Between Vitamin D Deficiency and Anemia in Pediatric Renal Transplant Recipients
(2022) Avci, Begum; Baskin, Esra; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Karakaya, Emre; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-5375-379X; 0000-0002-3462-7632; 0000-0002-4879-7974; AAJ-8833-2021; GYU-5220-2022; AAJ-8097-2021; AAD-5466-2021
BK Polyomavirus Infection and Risk Factors in Pediatric Patients Undergoing Kidney Transplant
(2022) Avci, Begum; Baskin, Esra; Gulleroglu, Kaan; Ecevit, Zafer; Soy, Ebru Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; 35570612
Objectives: BK polyomavirus infection is a critical complication affecting graft survival after kidney transplant. We aimed to determine the frequency, the effect on graft function, and the risk factors of BK polyomavirus infection in pediatric kidney transplant patients. Materials and Methods: We retrospectively reviewed data of 144 pediatric patients (female/male: 67/77; 0-18 years of age) who received kidney transplants in the past 10 years at our center. Demographic/laboratory data, kidney failure etiologies, donor types, and immunosuppressive treatments were recorded. Patients were grouped as those with and without BKV infection, with groups compared in terms of transplant age, sex, kidney failure etiology, donor type, immunosuppressive treatments, presence of ureteral stents, acute rejection episodes, accompanying viral infections, glomerular filtration rate, and graft loss rate. Results: Twelve patients (8.3%) had BK polyomavirus infection. All 12 patients had viruria (8.3%), 8 (5.5%) had viremia, and 4 (2.8%) had BK polyomavirus nephropathy. Two patients (1.4%) had graft loss because of BK polyomavirus nephropathy. When patients with and without infection were compared, no significant differences were found in terms of sex, transplant age, donor type, presence of a ureteral stent, acute rejection, graft loss, or immunosuppressive treatment (P > .05). Rates of congenital anomalies of the kidney and urinary tract were 30.3% and 66.6% in those without and with BK polyomavirus infection, respectively (P < .05). The group positive for BK polyomavirus had a significantly higher incidence of cytomegalovirus infection versus the group without infection (P < .05). Glomerular filtration rate values at years 1 and 3 were similar between groups (P > .05). Conclusions: Frequency of BK polyomavirus nephropathy in pediatric patients undergoing kidney transplant in our center was consistent with data from other centers. Graft loss can be prevented by early detection and treatment through close periodic control and adequate evaluation of risk factors.
CLINICAL IMPACT OF COMPLEMENT DEPOSITION FINDINGS ON BIOPSIES IN ACUTE REJECTION EPISODES OF PEDIATRIC RENAL TRANSPLANT PATIENTS
(2020) Gulleroglu, Kaan; Baskin, Esra; Ozdemir, B. Handan; Yilmaz, Aysun Caltik; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet A.
Clinical impact of complement deposition findings on biopsies in acute rejection episodes of pediatric renal transplant patients
(2021) Gulleroglu, Kaan; Baskin, Esra; Ozdemir, Handan; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-3462-7632; 34508854; AAJ-8833-2021; AAJ-8097-2021
Introduction: Rejection is the most important problem for renal graft function and survival. Complement system plays a key role in immune responses from host to graft. It was demonstrated that complement system activation is related with renal fibrosis. We evaluate clinical impact of complement deposition findings on biopsies in acute rejection episodes of pediatric renal transplant patients. Method: Demographics of the patients, graft functions, acute rejection episodes and graft loss were recorded from data files of 165 pediatric renal transplant patients. Findings of 98 renal biopsies were retrospectively evaluated. Results: Thirty three patients with kidney transplant had 44 acute rejection episodes (32 pure cellular acute rejection episodes / 1 pure humoral acute rejection episode / 11 combined acute cellular and acute humoral rejection episodes) proven by biopsy. C1q staining was positive in 7 biopsies, C3 staining in 15 biopsies and, C4d staining in 15 biopsies. 26 patients had graft fibrosis. All patients with a rejection history had a significant decrease in GFR value during follow-up. Patients who did not have fibrotic changes in first biopsy had same level of deterioration of GFR when compared with patients who had fibrotic changes in first biopsy. Conclusion: We could not demonstrate a significant relation between complement deposition and renal fibrosis, and between complement deposition and GFR values. Our data demonstrated that graft outcomes and graft loss after acute rejection episodes cannot be predicted only with complement deposition on graft or only with graft fibrosis.
Covid-19 In Pediatric Nephrology Centers In Turkey
(2021) Gulleroglu, Kaan
COVID-19 Infections in Pediatric Renal Transplant Recipients
(2022) Yilmaz, Aysun Caltik; Baskin, Esra; Gulleroglu, Kaan; Karakaya, Deniz; Akdur, Aydincan; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-0774-4419; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-3462-7632; 35384829; AAD-1877-2021; AAJ-8833-2021; AAJ-8097-2021
Objectives: The new coronavirus SARS-CoV-2 (COVID-19) first appeared in Turkey in March 2020, spread rapidly, and caused many deaths. Although COVID-19 is mostly a respiratory disease, it can cause kidney and multiorgan failure in some cases. We believe that by sharing information about the course and effects of COVID-19 infection in kidney transplant recipients receiving long-term immunosuppressive therapy our understanding will improve. Materials and Methods: Between March 2020 and October 2021, COVID-19 was researched in kidney transplant recipients under the age of 20 years who were followed at the Baskent University Transplantation Center. We documented the clinical characteristics and prognosis of pediatric kidney transplant recipients with COVID-19 disease. Results: Our study group included 23 patients with COVID-19 infection from 215 pediatric kidney transplant recipients. The mean age of the patients was 14.6 +/- 4.7 years; there were 9 female patients. The mean follow-up time posttransplant was 62.3 +/- 43.2 months. In 13 patients (56.5%), fever was the most frequent symptom. Most patients (n = 18, 78%) had minor symptoms and recovered completely after receiving supportive treatment. Four patients (17%) required hospitalization. One was diagnosed with COVID-19 infection 1 week after being treated with rituximab for acute antibody-mediated rejection. That patient died because of significant lung disease and multiorgan failure. Conclusions: Despite the fact that most of our pediatric transplant recipients had mild symptoms of COVID-19, we believe that particular caution should be observed in patients who have recently received intensive immunosuppressive medications. As a result of potential new vaccines, national immunization programs, and the emergence of novel virus strains, the clinical picture may change in the future. We believe that, as information sharing increases, we will learn more about COVID-19 in renal transplant recipients.
Early post-transplant blood transfusions and graft outcome in pediatric renal transplant recipients
(2019) Baskin, Esra; Kazanci, Ozlem; Uslu, Nihal; Gulleroglu, Kaan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0003-4361-8508; AAC-5566-2019; ABC-5258-2020; B-5785-2018
EARLY POST-TRANSPLANT BLOOD TRANSFUSIONS AND GRAFT OUTCOME IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS
(2019) Baskin, Esra; Kazanci, Ozlem; Uslu, Nihal; Gulleroglu, Kaan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; AAC-5566-2019
Eculizumab in the Treatment of Dense Deposit Disease
(2015) Gulleroglu, Kaan; Avci, Begum; Kantar, Asli; Ozdemir, Handan; Baskin, Esra; 0000-0002-5375-379X; 0000-0003-1434-3824; 0000-0002-7528-3557; 0000-0003-1434-3824; 0000-0003-4361-8508; GYU-5220-2022; AAJ-8833-2021; X-8540-2019; F-3294-2013; B-5785-2018
Eculizumab Therapy for Late Antibody-Mediated Rejection in Pediatric Kidney Transplant Patients
(2022) Siddiqui, Meraj Alam; Baskin, Esra; Karakayali, Feza Yarbug; Gemici, Atilla; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-3462-7632; AAJ-8833-2021; AAJ-8097-2021
Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study
(2022) Baskin, Esra; Fidan, Kibriya; Gulhan, Bora; Gulleroglu, Kaan; Canpolat, Nur; Yilmaz, Alev; Parmakiz, Gonul; Ozcakar, Birsin Z.; Ozaltin, Fatih; Soylemezoglu, Oguz; 35060104
Introduction Eculizumab is effective treatment of pediatric atypical hemolytic uremic syndrome (aHUS). However, the optimal duration of treatment is not clearly defined. The aim of this study was to retrospectively analyze the outcome of pediatric patients with aHUS, who started eculizumab treatment but discontinued it during the follow-up period. Methods The clinical and laboratory findings of the pediatric patients with aHUS were recorded on a web-based, national registry system, known as the Turkish aHUS Registry. The study included 63 patients who had to have received more than four doses of eculizumab during the acute phase of the disease. Results The median age at diagnosis was 3.62 (IQR: 1.29-6.14) years. During the follow-up period, 39 patients continued to receive standard eculizumab treatment (standard treatment group, treatment every 2 weeks) while 24 received an extended dose of eculizumab at three-four-week intervals (non-standard treatment group). There was no significant difference between both groups in terms of clinical and laboratory parameters. Eculizumab treatment was discontinued in 18 patients (30.7%, F/M:11/7), and the median age of these patients at diagnosis and their median follow-up duration were 4.0 (IQR:2.7-10.2) and 4.2 (IQR:2.2-7) years respectively. The median eGFR at the last visit was 110 (84.7-146.1)ml/min/1.73 m(2). Fourteen patients remained in remission without any sign of the disease. Recurrence occurred in four (22.2%) patients, in which eculizumab was immediately started again and complete remission was achieved. Conclusion Eculizumab is a successful treatment option in pediatric patients with aHUS and it can be safely discontinued with close monitoring in a selected group of patients. In case of recurrence, eculizumab should be restarted immediately to achieve complete remission. [GRAPHICS] .
The Effect of Anti-hla Antibodies on Renal Graft Functions
(2014) Baskin, Esra; Gulleroglu, Kaan; Kantar, Asli; Kirnap, Mahir; Karakayali, Feza; Haberal, Aysegul; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-1874-947X; https://orcid.org/0000-0003-2498-7287; https://orcid.org/0000-0002-3462-7632; B-5785-2018; F-3294-2013; AAH-9198-2019; AAB-3888-2021; AAE-1041-2021; AAJ-8097-2021
The Effect of Pretransplant Long Term Anuria on Graft Outcome in Children
(2017) Avci, Begum; Baskin, Esra; Gulleroglu, Kaan; Kazanci, Ozlem; Kirnap, Mahir; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0003-4361-8508; 0000-0003-1434-3824; 0000-0002-3462-7632; 0000-0002-5375-379X; 0000-0003-2498-7287; F-3294-2013; AAH-9198-2019; B-5785-2018; AAJ-8833-2021; AAJ-8097-2021; GYU-5220-2022; AAE-1041-2021
Effects of Early Post-Transplant Blood Transfusion on Graft Outcome in Pediatric Renal Transplant Recipients
(2018) Kazanci, Ozlem; Baskin, Esra; Gulleroglu, Kaan; Avci, Begum; Soy, Ebru H. Ayvazoglu; Sahin, Vildan; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-4361-8508; ttps://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-5375-379X; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0003-2498-7287; https://orcid.org/0000-0002-3462-7632; B-5785-2018; AAJ-8833-2021; GYU-5220-2022; AAC-5566-2019; AAE-1041-2021; AAJ-8097-2021
Effects of Early Post-Transplant Blood Transfusion on Graft Outcome in Pediatric Renaltransplant Recipients
(2018) Kazanci, Ozlem; Baskin, Esra; Gulleroglu, Kaan; Sahin, Vildan; Avci, Begum; Toy, Ebru Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; 0000-0003-4361-8508; 0000-0003-1434-3824; 0000-0002-5375-379X; 0000-0003-2498-7287; 0000-0002-3462-7632; B-5785-2018; F-3294-2013; GYU-5220-2022; AAE-1041-2021; AAJ-8097-2021
The Effects of Graft Weight on Allograft Outcomes in Pediatric Patients
(2018) Gulleroglu, Kaan; Baskin, Esra; Soy, Ebru H. Ayvazoglu; Akdur, Aydincan; Yildirim, Sedat; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0003-4361-8508; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-5735-4315; 0000-0003-2498-7287; 0000-0002-3462-7632; AAJ-8833-2021; B-5785-2018; AAC-5566-2019; AAA-3068-2021; AAF-4610-2019; AAE-1041-2021; AAJ-8097-2021